Combination therapy before and after surgery for stage IIB-IIIB lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two medicines (penpulimab and anlotinib) plus chemotherapy given before and after surgery for stage IIB-IIIB non-small cell lung cancer. The goal is to see if this approach can shrink the tumor and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is stage IIB or IIIB (N2) and can be removed with surgery.
- Your tumor does not have certain gene changes (EGFR, ALK, or ROS1).
- You are well enough to walk and take care of yourself (ECOG 0-1) and are expected to live at least 12 more weeks.
- Your lungs are strong enough to handle the surgery.
- You have not had any prior cancer treatment (surgery, chemotherapy, or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
This trial tests whether giving a combination of two drugs (sintilimab and anlotinib) before surgery can help shrink non-small cell lung cancer tumors and improve outcomes. It is for people with stage IB to IIIB cancer that can be removed with surgery and who have not had treatment yet.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
Hear when a new Resectable Locally Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.